Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.81 |
| ▸ | MEN1 | O00255 | 7/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.81 |
| ▸ | MAPT | P10636 | 4/20 | 0.81 |
| ▸ | GFER | P55789 | 1/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.81 |
| ▸ | HPGD | P15428 | 3/20 | 0.81 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.69 |
| ▸ | POLB | P06746 | 4/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.66 |
| ▸ | TSHR | P16473 | 2/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.66 |
| ▸ | CASP1 | P29466 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | PIM1 | P11309 | 1/20 | 0.59 |
| ▸ | IP6K1 | Q92551 | 5/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | IP6K3 | Q96PC2 | 3/20 | 0.49 |
| ▸ | IP6K2 | Q9UHH9 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11632404 | 0.90 | ALDH1A1 (0.72) | ALDH1A1MEN1KMT2AMAPTGFER | |
| SCHEMBL11469513 | 0.90 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2AMAPTGFER | |
| SCHEMBL10933962 | 0.89 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2AMAPTGFER | |
| SCHEMBL12330213 | 0.86 | ALDH1A1 (0.63) | ALDH1A1MEN1KMT2AMAPTGFER | |
| SCHEMBL12401812 | 0.82 | ALDH1A1 (0.59) | ALDH1A1MEN1KMT2AMAPTGFER | |
| SCHEMBL4027586 | 0.80 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2AMAPTGFER | |
| SCHEMBL2505119 | 0.79 | ALDH1A1 (0.69) | ALDH1A1MEN1KMT2AMAPTGFER | |
| SCHEMBL2505118 | 0.79 | ALDH1A1 (0.69) | ALDH1A1MEN1KMT2AMAPTGFER | |
| SCHEMBL29941133 | 0.78 | PIM1 (0.66) | ALDH1A1MEN1KMT2AMAPTGFER | |
| SCHEMBL11629288 | 0.77 | ALDH1A1 (0.59) | ALDH1A1MEN1KMT2AMAPTGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841320-B2 | Targeted, NIR imaging agents for therapy efficacy monitoring, deep tissue disease demarcation and deep tissue imaging | VANDERBILT UNIVERSITY | 2014-09-23 | — | — | US | disclosed |
| US-8841320-B2 | Targeted, NIR imaging agents for therapy efficacy monitoring, deep tissue disease demarcation and deep tissue imaging | VANDERBILT UNIVERSITY | 2014-09-23 | — | — | US | disclosed |
| US-20130177502-A1 | Targeted, NIR Imaging Agents for Therapy Efficacy Monitoring, Deep Tissue Disease Demarcation and Deep Tissue Imaging | VANDERBILT UNIVERSITY (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130177502-A1 | Targeted, NIR Imaging Agents for Therapy Efficacy Monitoring, Deep Tissue Disease Demarcation and Deep Tissue Imaging | VANDERBILT UNIVERSITY (US) | 2013-07-11 | — | — | US | disclosed |
| US-8372868-B2 | Targeted, NIR imaging agents for therapy efficacy monitoring, deep tissue disease demarcation and deep tissue imaging | VANDERBILT UNIVERSITY (US) | 2013-02-12 | — | — | US | disclosed |
| US-8372868-B2 | Targeted, NIR imaging agents for therapy efficacy monitoring, deep tissue disease demarcation and deep tissue imaging | VANDERBILT UNIVERSITY (US) | 2013-02-12 | — | — | US | disclosed |
| US-8188116-B2 | Ligand/drug conjugates; near infrared radiation imaging; peripheral benzodiazepine receptor imaging; drug delivery; drug targets; cancer, metastasis | VANDERBILT UNIVERSITY (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188116-B2 | Ligand/drug conjugates; near infrared radiation imaging; peripheral benzodiazepine receptor imaging; drug delivery; drug targets; cancer, metastasis | VANDERBILT UNIVERSITY (US) | 2012-05-29 | — | — | US | disclosed |
| US-20100278739-A1 | TARGETED, NIR IMAGING AGENTS FOR THERAPY EFFICACY MONITORING, DEEP TISSUE DISEASE DEMARCATION AND DEEP TISSUE IMAGING | VANDERBILT UNIVERSITY | 2010-11-04 | — | — | US | disclosed |
| US-7754884-B2 | Targeted, NIR imaging agents for therapy efficacy monitoring, deep tissue disease demarcation and deep tissue imaging | VANDERBILT UNIVERSITY (US) | 2010-07-13 | — | — | US | disclosed |
| US-7754884-B2 | Targeted, NIR imaging agents for therapy efficacy monitoring, deep tissue disease demarcation and deep tissue imaging | VANDERBILT UNIVERSITY (US) | 2010-07-13 | — | — | US | disclosed |
| US-20080031823-A1 | AGENTS FOR THERAPY EFFICACY MONITORING AND DEEP TISSUE IMAGING | US GOVERNMENT - SECRETARY FOR THE ARMY | 2008-02-07 | — | — | US | disclosed |
| US-20080031823-A1 | AGENTS FOR THERAPY EFFICACY MONITORING AND DEEP TISSUE IMAGING | US GOVERNMENT - SECRETARY FOR THE ARMY | 2008-02-07 | — | — | US | disclosed |
| US-7205311-B2 | Therapeutic acridone and acridine compounds | CANCER RESEARCH TECHNOLOGY LIMITED | 2007-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080031823-A1 | AGENTS FOR THERAPY EFFICACY MONITORING AND DEEP TISSUE IMAGING | TSPO, MKI67, CNR1 | ALDH1A1 1393/4885MEN1 2657/4885KMT2A 3444/4885 |
| US-20100278739-A1 | TARGETED, NIR IMAGING AGENTS FOR THERAPY EFFICACY MONITORING, DEEP TISSUE DISEASE DEMARCATION AND DEEP TISSUE IMAGING | TSPO, MKI67, GABRA4 | ALDH1A1 881/4885MEN1 3250/4885KMT2A 2948/4885 |
| US-20130177502-A1 | Targeted, NIR Imaging Agents for Therapy Efficacy Monitoring, Deep Tissue Disease Demarcation and Deep Tissue Imaging | TSPO, MKI67, GABRA4 | ALDH1A1 881/4885MEN1 3250/4885KMT2A 2948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.